A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

PHASE3RecruitingINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Chikungunya Virus
Interventions
BIOLOGICAL

CHIKV VLP vaccine

CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%

BIOLOGICAL

Placebo

Placebo is comprised of formulation buffer

Trial Locations (9)

918

NOT_YET_RECRUITING

Caribbean Medicine Center, San Juan

20009

NOT_YET_RECRUITING

Emerson Clinical Research Institute- DC, Washington D.C.

33142

NOT_YET_RECRUITING

Acevedo Clinical Research, Miami

33166

ACTIVE_NOT_RECRUITING

Hope Research Network, Miami

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

68134

RECRUITING

Velocity Clinical Research-Omaha, Omaha

77706

RECRUITING

KidCare Pediatrics, Beaumont

84088

RECRUITING

Velocity Clinical Research - Salt Lake City, West Jordan

92708

RECRUITING

ARK Clinical Research, LLC, Fountain Valley

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT07003984 - A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. | Biotech Hunter | Biotech Hunter